Compare BNBX & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNBX | LYRA |
|---|---|---|
| Founded | 1983 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 5.6M |
| IPO Year | N/A | 2020 |
| Metric | BNBX | LYRA |
|---|---|---|
| Price | $1.56 | $1.71 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 280.3K | 129.9K |
| Earning Date | 02-12-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,136,935.00 | $600,000.00 |
| Revenue This Year | $253.12 | N/A |
| Revenue Next Year | N/A | $93.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.11 | N/A |
| 52 Week Low | $1.16 | $1.63 |
| 52 Week High | $145.73 | $37.50 |
| Indicator | BNBX | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 39.43 | 28.60 |
| Support Level | $1.50 | $1.63 |
| Resistance Level | $1.73 | $2.58 |
| Average True Range (ATR) | 0.16 | 0.30 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 42.87 | 3.90 |
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.